Courier Capital LLC increased its stake in shares of Danaher Co. (NYSE:DHR - Free Report) by 77.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,733 shares of the conglomerate's stock after acquiring an additional 1,627 shares during the quarter. Courier Capital LLC's holdings in Danaher were worth $765,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Spinnaker Trust lifted its stake in shares of Danaher by 1.2% in the fourth quarter. Spinnaker Trust now owns 4,304 shares of the conglomerate's stock valued at $988,000 after buying an additional 50 shares in the last quarter. Fortis Capital Advisors LLC lifted its stake in shares of Danaher by 1.3% in the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock valued at $914,000 after buying an additional 50 shares in the last quarter. Fayez Sarofim & Co lifted its stake in shares of Danaher by 0.6% in the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock valued at $1,902,000 after buying an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC lifted its stake in shares of Danaher by 4.8% in the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after buying an additional 50 shares in the last quarter. Finally, Perennial Investment Advisors LLC lifted its stake in shares of Danaher by 2.2% in the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock valued at $538,000 after buying an additional 51 shares in the last quarter. 79.05% of the stock is owned by institutional investors.
Danaher Stock Performance
Shares of DHR traded up $2.00 during trading hours on Wednesday, hitting $204.62. The company's stock had a trading volume of 4,491,382 shares, compared to its average volume of 3,494,407. The company has a market cap of $146.44 billion, a price-to-earnings ratio of 38.75, a PEG ratio of 2.66 and a beta of 0.77. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The business has a 50 day simple moving average of $191.32 and a two-hundred day simple moving average of $211.72. Danaher Co. has a 52-week low of $171.00 and a 52-week high of $281.70.
Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.26. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a net margin of 16.33% and a return on equity of 10.82%. On average, equities analysts expect that Danaher Co. will post 7.63 earnings per share for the current fiscal year.
Danaher Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.63%. Danaher's payout ratio is 24.85%.
Insider Transactions at Danaher
In other news, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the transaction, the executive vice president now directly owns 15,179 shares in the company, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman now owns 3,105,808 shares of the company's stock, valued at $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.10% of the company's stock.
Wall Street Analysts Forecast Growth
DHR has been the topic of several recent analyst reports. Bank of America dropped their price objective on Danaher from $265.00 to $230.00 in a research note on Monday, April 14th. Robert W. Baird lowered their target price on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Royal Bank of Canada reiterated an "outperform" rating and issued a $250.00 target price on shares of Danaher in a report on Wednesday, April 23rd. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Finally, Stifel Nicolaus upgraded shares of Danaher from a "hold" rating to a "buy" rating and set a $260.00 target price for the company in a report on Friday, March 14th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $248.17.
Check Out Our Latest Analysis on DHR
Danaher Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
